Wednesday, 26 August 2026European Markets

NYXOAH Stock Bearish By 13% So Far Today

Loading stream...

(VIANEWS) - Shares of NYXOAH (BEL 20: NYXH.BR) slid by a staggering 13.55% to €7.02 at 11:23 EST on Monday, after two consecutive sessions in a row of losses. BEL 20 is jumping 0.07% to €3,829.14, following the last session's upward trend. This seems, at the moment, a somewhat up trend exchanging session today.

NYXOAH's last close was €8.12, 52.57% below its 52-week high of €17.12.

About NYXOAH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-1.12.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -23.22%.

Volume

Today's last reported volume for NYXOAH is 86506 which is 381.44% above its average volume of 17968.

More news about NYXOAH (NYXH.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com